Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.28 +4.6%	$0.27	$0.20 ▼ $1.48	$74.48M	2.18	1.36 million shs	562,667 shs
AUTL Autolus Therapeutics	$2.65 +7.3%	$1.92	$1.11 ▼ $5.00	$705.27M	1.81	1.78 million shs	1.87 million shs
NK NantKwest	$2.81 -2.1%	$28.01	$2.52 ▼ $45.42	$307.26M	2.61	1.57 million shs	6.04 million shs
TBIO Telesis Bio	$0.02 -91.9%	$0.12	$0.01 ▼ $6.17	$44K	0.96	6,682 shs	663 shs
VYGR Voyager Therapeutics	$3.43 -1.7%	$3.20	$2.64 ▼ $9.55	$189.82M	0.85	476,144 shs	491,566 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	+7.01%	+10.85%	+14.84%	-79.02%
AUTL Autolus Therapeutics	0.00%	+4.22%	+16.51%	+84.33%	-41.88%
NK NantKwest	0.00%	+3.31%	-11.91%	+6.84%	-57.55%
TBIO Telesis Bio	0.00%	0.00%	+500.00%	-60.00%	-91.83%
VYGR Voyager Therapeutics	0.00%	+6.40%	+5.76%	+9.40%	-60.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	1.9764 of 5 stars	3.1	4.0	0.0	0.0	2.2	0.8	0.0
AUTL Autolus Therapeutics	2.8669 of 5 stars	3.5	1.0	0.0	0.0	3.3	3.3	0.6
NK NantKwest	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TBIO Telesis Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.978 of 5 stars	3.6	2.0	0.0	4.6	2.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	381.02% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	251.70% Upside
NK NantKwest	0.00	N/A	N/A	N/A
TBIO Telesis Bio	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.13	Buy	$13.39	290.38% Upside

Current Analyst Ratings Breakdown

Latest ADAP, NK, TBIO, AUTL, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.42	N/A	N/A	$0.05 per share	5.62
AUTL Autolus Therapeutics	$10.12M	69.69	N/A	N/A	$1.61 per share	1.65
NK NantKwest	$40K	7,681.49	N/A	N/A	$1.23 per share	2.28
TBIO Telesis Bio	$225.09M	0.00	N/A	N/A	$0.14 per share	0.17
VYGR Voyager Therapeutics	$80M	2.37	N/A	N/A	$5.49 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
NK NantKwest	-$65.79M	-$0.70	N/A	N/A	N/A	-76,658.58%	-56.06%	-46.93%	N/A
TBIO Telesis Bio	-$47.72M	-$28.20	N/A	∞	N/A	-336.59%	N/A	-61.89%	8/5/2025 (Estimated)
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)

Latest ADAP, NK, TBIO, AUTL, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	N/A	N/A	N/A	$11.04 million	N/A
8/8/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/5/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	N/A	N/A	N/A	$9.50 million	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
NK NantKwest	N/A	N/A	N/A	N/A	N/A
TBIO Telesis Bio	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
AUTL Autolus Therapeutics	N/A	9.24	9.02
NK NantKwest	N/A	4.74	4.74
TBIO Telesis Bio	N/A	1.23	1.06
VYGR Voyager Therapeutics	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
AUTL Autolus Therapeutics	72.83%
NK NantKwest	9.38%
TBIO Telesis Bio	37.63%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
AUTL Autolus Therapeutics	25.70%
NK NantKwest	71.73%
TBIO Telesis Bio	24.50%
VYGR Voyager Therapeutics	4.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
NK NantKwest	160	109.35 million	N/A	Not Optionable
TBIO Telesis Bio	200	1.80 million	1.36 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.83 million	Optionable

ADAP, NK, TBIO, AUTL, and VYGR Headlines

Recent News About These Companies

Embark On a Summer Adventure Abroad Star Voyager Cruise to Naha, Sanya and More

2 hours ago | prestigeonline.comP

Voyager’s Tim Russ Doesn’t Think a Black Vulcan Is a Feat for Star Trek

2 hours ago | fandomwire.comF

UK awards AirTanker network node upgrade for Voyager

July 11 at 10:28 AM | janes.comJ

Voyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current Technology

July 10, 2025 | msn.com

Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39

July 8, 2025 | americanbankingnews.com

RNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'

July 7, 2025 | itv.comI

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager

July 6, 2025 | cruiseindustrynews.comC

With Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-Wallets

July 5, 2025 | travelmole.comT

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

July 5, 2025 | marketbeat.com

Ant International launches Alipay+ Voyager, an AI-powered travel assistant inside e-wallets

July 3, 2025 | walastech.comW

VYGR Voyager Therapeutics, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

Major Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With Paint

June 20, 2025 | theaviationist.comT

Protesters Vandalize RAF Voyager Tankers In Palestine Protest

June 20, 2025 | aviationweek.comA

Voyager Technologies Soars with IPO Success

June 14, 2025 | devdiscourse.comD

Space Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss Expansion

June 12, 2025 | devdiscourse.comD

Voyager Technologies Rises in Debut, Signaling Improving IPO Market

June 12, 2025 | msn.com

Voyager soars 82% on first day of trading as defense tech booms

June 12, 2025 | msn.com

Investor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOs

June 11, 2025 | msn.com

Voyager Technologies' Shares More Than Double in NYSE Debut

June 11, 2025 | marketwatch.com

Voyager Technologies Shares Soar In Market Debut

June 11, 2025 | news.crunchbase.comN

Space tech firm Voyager valued at $3.8 billion as shares surge in NYSE debut

June 11, 2025 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
By Gabriel Osorio-Mazilli | July 3, 2025
View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
3 Summer Short-Squeeze Candidates With Catalysts for Covering
By Thomas Hughes | June 30, 2025
View 3 Summer Short-Squeeze Candidates With Catalysts for Covering

ADAP, NK, TBIO, AUTL, and VYGR Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.28 +0.01 (+4.62%)

Closing price 04:00 PM Eastern

Extended Trading

$0.27 -0.01 (-2.85%)

As of 07:57 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Autolus Therapeutics NASDAQ:AUTL

$2.65 +0.18 (+7.29%)

Closing price 04:00 PM Eastern

Extended Trading

$2.67 +0.02 (+0.75%)

As of 07:55 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

NantKwest NASDAQ:NK

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Telesis Bio NASDAQ:TBIO

$0.02 -0.28 (-91.90%)

As of 02:53 PM Eastern

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Voyager Therapeutics NASDAQ:VYGR

$3.43 -0.06 (-1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$3.49 +0.06 (+1.72%)

As of 07:31 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time